Company intelligence / Profile preview
Fosun Kairos
Shanghai, Shanghai Municipality, Chinafosunkairos.com ↗
- Ownership
- Private
- Employees
- ~63
- Development stage
- Other
01
Overview
Yi Kai Da, the company’s flagship autologous anti-CD19 CAR-T therapy, was the first and remains the only CAR-T product approved for second-line use in mainland China. It has been included in over a hundred commercial health insurance plans. The company operates more than 170 treatment centers across China. Other pipeline assets are at preclinical or early clinical stages targeting hematologic malignancies and solid tumors.
- Therapeutic areas
- Oncology
- Modalities
- Autologous CAR-T cell therapiesBispecific antibodiesBiological products
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Former joint venture with Kite Pharma Inc.ongoing license agreement with Kite Pharma regarding key technology/IP
Beyond the preview
Go deeper on Fosun Kairos.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fosun Kairos.